PURPOSE: [N-methyl-11C]alpha-methylaminoisobutyric acid ([11C]MeAIB) is a promising positron emission tomography (PET) tracer for imaging hormonally regulated system A amino acid transport. Uptake of [11C]MeAIB is totally specific for amino acid transport since [11C]MeAIB is metabolically stable both extra- and intracellularly. The aim of this study was to measure cumulated radioactivity in different organs and estimate the absorbed radiation doses to humans with the Medical Internal Radiation Dosimetry (MIRD) method. METHODS: Radiation absorbed doses were calculated from PET images for 25 volunteers. Dynamic acquisition data were obtained for the thoracic, abdominal, femoral and head and neck regions. The median dose of intravenously injected [11C]MeAIB was 422+/-35 MBq, with a range of 295-493 MBq. After PET imaging the radioactivity in voided urine was measured. Experimental human data were used for residence time estimates. Radiation doses were calculated with commonly used software. RESULTS: The effective dose for a 70-kg adult was 0.004 mSv/MBq, corresponding to a 1.72 mSv effective dose from the PET study with injection of 430 MBq [11C]MeAIB. The highest absorbed doses were in the pancreas (0.018 mGy/MBq), kidneys (0.017 mGy/MBq), intestine (0.014 mGy/MBq), liver (0.008 mGy/MBq) and stomach (0.005 mGy/MBq). Only 0.57% of injected activity was excreted to urine within 1 h after injection. CONCLUSION: Biodistribution of [11C]MeAIB in the abdominal region reflected the high activity of the transportation of amino acids via system A and these organs also had the highest radiation doses. An effective dose of 0.004 mSv/MBq is fully justified when [11C]MeAIB PET is performed to study system A activity in vivo.
PURPOSE:[N-methyl-11C]alpha-methylaminoisobutyric acid ([11C]MeAIB) is a promising positron emission tomography (PET) tracer for imaging hormonally regulated system A amino acid transport. Uptake of [11C]MeAIB is totally specific for amino acid transport since [11C]MeAIB is metabolically stable both extra- and intracellularly. The aim of this study was to measure cumulated radioactivity in different organs and estimate the absorbed radiation doses to humans with the Medical Internal Radiation Dosimetry (MIRD) method. METHODS: Radiation absorbed doses were calculated from PET images for 25 volunteers. Dynamic acquisition data were obtained for the thoracic, abdominal, femoral and head and neck regions. The median dose of intravenously injected [11C]MeAIB was 422+/-35 MBq, with a range of 295-493 MBq. After PET imaging the radioactivity in voided urine was measured. Experimental human data were used for residence time estimates. Radiation doses were calculated with commonly used software. RESULTS: The effective dose for a 70-kg adult was 0.004 mSv/MBq, corresponding to a 1.72 mSv effective dose from the PET study with injection of 430 MBq [11C]MeAIB. The highest absorbed doses were in the pancreas (0.018 mGy/MBq), kidneys (0.017 mGy/MBq), intestine (0.014 mGy/MBq), liver (0.008 mGy/MBq) and stomach (0.005 mGy/MBq). Only 0.57% of injected activity was excreted to urine within 1 h after injection. CONCLUSION: Biodistribution of [11C]MeAIB in the abdominal region reflected the high activity of the transportation of amino acids via system A and these organs also had the highest radiation doses. An effective dose of 0.004 mSv/MBq is fully justified when [11C]MeAIB PET is performed to study system A activity in vivo.
Authors: T A Deterding; J R Votaw; C K Wang; D Eshima; L Eshima; R Keil; E Malveaux; C D Kilts; M M Goodman; J M Hoffman Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057
Authors: Tuula Tolvanen; Kaisa Lehtiö; Jarmo Kulmala; Vesa Oikonen; Olli Eskola; Jörgen Bergman; Heikki Minn Journal: J Nucl Med Date: 2002-12 Impact factor: 10.057
Authors: Lionel G Bouchet; Wesley E Bolch; H Pablo Blanco; Barry W Wessels; Jeffry A Siegel; Didier A Rajon; Isabelle Clairand; George Sgouros Journal: J Nucl Med Date: 2003-07 Impact factor: 10.057
Authors: M M Graham; L M Peterson; J M Link; M L Evans; J S Rasey; W J Koh; J H Caldwell; K A Krohn Journal: J Nucl Med Date: 1997-10 Impact factor: 10.057
Authors: Hubert Vesselle; John Grierson; Lanell M Peterson; Mark Muzi; David A Mankoff; Kenneth A Krohn Journal: J Nucl Med Date: 2003-09 Impact factor: 10.057
Authors: Markku R Asola; Kirsi A Virtanen; Pauliina Peltoniemi; Kjell Någren; Meixiang Yu; Kari Mattila; Sirkku Jyrkkiö; Kaj Metsärinne; Pirjo Nuutila; Juhani Knuuti Journal: Eur J Nucl Med Mol Imaging Date: 2002-08-30 Impact factor: 9.236
Authors: Limin Wang; Zhihao Zha; Wenchao Qu; Hongwen Qiao; Brian P Lieberman; Karl Plössl; Hank F Kung Journal: Nucl Med Biol Date: 2012-04-26 Impact factor: 2.408
Authors: Allison S Cohen; Joe Grudzinski; Gary T Smith; Todd E Peterson; Jennifer G Whisenant; Tiffany L Hickman; Kristen K Ciombor; Dana Cardin; Cathy Eng; Laura W Goff; Satya Das; Robert J Coffey; Jordan D Berlin; H Charles Manning Journal: J Nucl Med Date: 2021-04-30 Impact factor: 11.082